Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply
Eur J Heart Fail
.
2022 Aug;24(8):1450-1451.
doi: 10.1002/ejhf.2611.
Epub 2022 Jul 19.
Authors
Nestor Rubio-Infante
1
,
Yoel A Ramírez-Flores
1
,
Elena C Castillo
1
,
Omar Lozano
1
2
,
Gerardo García-Rivas
1
2
3
,
Guillermo Torre-Amione
1
2
4
Affiliations
1
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Cátedra de Cardiología y Medicina Vascular, Monterrey, Mexico.
2
Tecnologico de Monterrey, Centro de Investigación Biomédica, Hospital Zambrano Hellion, TecSalud, San Pedro Garza García, Mexico.
3
Tecnologico de Monterrey, Centro de Medicina Funcional, Hospital Zambrano Hellion, TecSalud, San Pedro Garza García, Mexico.
4
The Methodist Hospital, Cornell University, Houston, TX, USA.
PMID:
35798652
DOI:
10.1002/ejhf.2611
No abstract available
Publication types
Letter
Meta-Analysis
Comment
MeSH terms
Cardiotoxicity / etiology
Heart Failure*
Humans
Immune Checkpoint Inhibitors / adverse effects
Neoplasms* / drug therapy
Substances
Immune Checkpoint Inhibitors